Highest-materiality recent filing
Sutro Q1 cash $202.6M; revenue $14.5M; luvelta closed; STRO-004 data mid-2026
Cash $202.6M as of Mar 31, 2026 (vs $141.4M Dec 2025); $110M stock offering extends runway into Q2 2028.
Sutro Biopharma reports FY2025 revenue $102.5M; cash runway extended into Q2 2028
Cash $141.4M at Dec 31, 2025; $110M underwritten offering extends runway into Q2 2028.
Sutro Biopharma raises $110M in underwritten public offering of 7.87M shares at $13.98/share
Offering of 7,868,383 shares at $13.98 per share; gross proceeds approximately $110.0 million.
Sutro Biopharma regains Nasdaq minimum bid price compliance after prior deficiency
Received Nasdaq notice on Dec 17, 2025 confirming compliance with Listing Rule 5450(a)(1) after 10 consecutive business days with closing bid at or above $1.00.
Sutro Biopharma announces 1-for-10 reverse stock split effective Dec 3 to regain Nasdaq compliance
Reverse stock split at 1-for-10, effective 12:01 a.m. ET on December 3, 2025.
Sutro Biopharma Q3 revenue $9.7M, cash $167.6M; IND cleared for STRO-004
FDA cleared IND for STRO-004 (Tissue Factor ADC); first patient dosing expected before year-end.
Sutro Biopharma cuts workforce ~33%; extends cash runway to mid-2027
Workforce reduction of approximately one-third to prioritize three preclinical ADC programs.
Sutro Q2 revenue $63.7M; cash $205.1M; STRO-004 IND on track for H2 2025
Q2 revenue $63.7M, up 148% YoY, driven by Astellas collaboration and Ipsen deferred revenue recognition.
Sutro Biopharma receives Nasdaq minimum bid price deficiency notice; has until Dec 17, 2025 to cure
Nasdaq notified Sutro on June 20, 2025 of non-compliance with $1.00 minimum bid price rule.
Sutro Biopharma stockholders approve reverse stock split at 1:5 to 1:25 ratio
Reverse stock split authorized at ratio between 1:5 and 1:25, board to set exact ratio.
Sutro Biopharma appoints Gregory K. Chow as CFO effective June 2, 2025
Gregory K. Chow appointed CFO, principal financial and accounting officer, effective June 2, 2025.
On June 2, 2025 Sutro Biopharma, Inc. (the “Company”) announced the appointment of Gregory K. Chow as its Chief Financial Officer, principal financial officer and principal accounting officer, effective as of June 2, 2025.
Max materiality 0.75 · Median 0.70 · Most common event other_material